20-Bio-A1 Biomaterials and Biocompatibility · December 2014
Nivaar worked solution (AI-drafted; not reviewed by a licensed engineer)
Paper format: National Exams, December 2014 — 04-Bio-A1 Biomaterials and Biocompatibility. Three hours, open book, any non-communicating calculator. Seven questions of equal value (20 marks each, 100 marks total); five constitute a complete paper and only the first five appearing in the answer book are marked. All seven are solved here, because this set is a study resource rather than an examination script. Every question is qualitative/descriptive (materials selection, surface science, host response) rather than numerical, except Question 7, which asks for an engineering interpretation of a small stress–strain data set — that question therefore quotes and reasons from the given numbers while still answering in flowing prose, as the question itself calls for discussion rather than a computed final answer.
Reference texts (the books an open-book candidate should have on the desk for this subject):
Question text not reproduced: the examination questions are © Engineers and Geoscientists BC. Open the official past paper (linked at the top of this page) to read the question, then follow the worked solution below.
Bringing a new contact lens material from bench to market requires work across several linked technical areas. Bulk material chemistry and processing comes first: silicone hydrogels are copolymerized from a hydrophobic siloxane macromer (which supplies oxygen permeability) and a hydrophilic comonomer (which supplies wettability and comfort), and the ratio, cross-link density, and cure chemistry must be controlled to give a reproducible, moldable, autoclavable material. Surface chemistry and modification is the area specific to this acquisition: native silicone is hydrophobic and fouls readily with tear-film lipids and proteins, so the "novel modification" almost certainly refers to a plasma-oxidation surface treatment, a grafted hydrophilic polymer brush, or an internal wetting agent that migrates to the surface — each approach must be characterized (contact angle, XPS surface composition, durability of the treatment under lens care and blinking) to prove the fouling-resistance claim is real and stable over the lens's wear life. Optical and dimensional engineering (refractive index, precise curvature and thickness control, dimensional stability on hydration) is unique to an ophthalmic device and has no equivalent in, say, an orthopedic implant. Biocompatibility and toxicology testing (ISO 10993 ocular-contact battery: cytotoxicity, sensitization, ocular irritation) must confirm the surface modification introduces no new leachables. Finally, manufacturing and quality control (unit-to-unit reproducibility of a mass-produced, low-cost, disposable device) and regulatory submission (Health Canada / FDA Class II medical device pathway) close the loop from laboratory material to a sellable product.
These technical areas differ from other biomaterials products chiefly in where the material has to succeed. A contact lens is a surface (mucosal/epithelial) contact device worn against a living, self-repairing but delicate corneal epithelium bathed in a dynamic tear film — the dominant design drivers are oxygen transmissibility (Dk/t) to avoid corneal hypoxia, wettability and lubricity for comfort, and resistance to microbial and protein/lipid fouling for infection control, none of which apply to a blood-contacting or load-bearing implant. By contrast, a vascular graft (Question 3) must resist thrombosis in flowing blood, and a hip implant (Question 4) must survive millions of cyclic mechanical loads while osseointegrating; a contact lens experiences comparatively low mechanical demand but very high daily handling and a chemically reactive, protein-rich fluid environment. This means the specific failure modes, the relevant characterization tests, and even the regulatory device class differ substantially between these three product families even though all are "biomaterials".
From the materials-aspects perspective, the acquisition target's success should be judged against: (1) biocompatibility — a clean ISO 10993 ocular battery (no cytotoxicity, sensitization, or irritation) for both the bulk polymer and any leachable from the fouling-resistant surface treatment; (2) oxygen permeability (Dk/t) sufficient to avoid corneal oedema and hypoxia-related complications during the intended wear schedule (daily vs. extended wear); (3) surface wettability and lubricity — a stable, low, reproducible contact angle across the intended wear period, since this governs comfort and is also the mechanism by which fouling resistance is claimed to work; (4) demonstrated, durable resistance to protein and lipid deposition under simulated and, eventually, clinical wear — the central claim of the acquisition, so it must be validated with real tear-film-representative soak tests and not just clean-buffer contact-angle data; (5) mechanical and dimensional stability (modulus low enough for comfort, but the lens must not warp, tear on removal, or drift out of its designed base curve on hydration); (6) manufacturability — can the surface modification be applied with tight, reproducible tolerances at mass-production scale and cost; and (7) regulatory and IP position — freedom to operate on the modification chemistry and a clear ISO 10993/Health Canada approval pathway. A "yes" on the underlying chemistry but a "no" on reproducible, scalable surface-treatment durability would be the most common way such an acquisition fails after the fact.
A due-diligence report to the economic team would translate these criteria into a short risk register: e.g., "Dk/t measured above the Holden–Mertz daily-wear threshold (about 24×10−9 (cm/s)(mL O2/mL·mmHg)), LOW risk; fouling-resistance durability beyond 30 days of simulated wear, UNTESTED, HIGH risk; surface-treatment process yield at pilot scale, UNKNOWN, MEDIUM risk" — giving a materials-grounded basis for the acquisition price and integration timeline rather than a marketing claim taken at face value.
